Please login to the form below

Not currently logged in
Email:
Password:

Takeda acquires Nycomed

Takeda Pharmaceutical Company has completed a €9.6bn takeover of Nycomed

Takeda Pharmaceutical Company has acquired Nycomed for €9.6bn on a cash-free, debt-free basis.

The boards of directors of each company unanimously approved the transaction that is expected to be completed within 90 to 120 days, making it a wholly owned subsidiary of Takeda, subject to antitrust clearance. The purchase would exclude Nycomed's US dermatology business.

Takeda said: "This transformational transaction is a strategic fit with Takeda's sustainable growth strategy as it was outlined in its 2011–2013 mid-range plan. Takeda has its strong presence in the Japanese and US markets, while Nycomed has a significant business infrastructure in Europe and high-growth emerging markets that will enhance Takeda's regulatory development expertise and commercialisation capability."

The acquisition includes the roflumilast franchise, a first-in-class treatment for chronic obstructive pulmonary disease, which is expected to be a major source of revenue growth for Takeda.

19th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics